What is "Ozempic face"?
"Ozempic face" is the informal term for the facial volume loss and skin laxity that can occur with rapid weight loss from GLP-1 receptor agonist medications — including Ozempic, Wegovy, Mounjaro, and Zepbound (Tirzepatide). The name stuck after widespread media coverage of celebrities and patients noting that dramatic weight loss had left their faces looking hollowed, gaunt, or more aged despite achieving a lower body weight.
The phenomenon is not specific to GLP-1 medications — it happens with any form of rapid weight loss. But because GLP-1 drugs have become one of the most prescribed medications in the country, the scale of patients experiencing facial changes has made it a mainstream conversation. At Plump Medical Spa in Newport Beach, Dr. Mortazavi prescribes Tirzepatide and treats the aesthetic consequences of GLP-1 weight loss in the same practice — an integrated approach that most providers do not offer.
Why the face shows it first
The face stores fat in small, diffuse deposits across the cheeks, temples, under-eyes, and jawline that contribute to the structural foundation of facial appearance. The body tends to metabolize facial fat disproportionately during rapid weight loss — more quickly than subcutaneous fat in the abdomen or thighs. The result is that patients achieve their weight goal but look older, more tired, or more gaunt than expected — because facial volume that was doing structural work has disappeared.
The signs to look for
1
Hollow cheeks
Cheek fat pads deflate, creating a sunken appearance where the face previously had fullness and structure.
2
Sunken under-eyes
Tear trough hollowing deepens as periorbital fat volume decreases, creating a more tired, aged appearance.
3
Deeper nasolabial folds
Loss of midface volume causes the skin to descend, deepening the lines between nose and mouth.
4
Jowling and laxity
Skin that previously had fat beneath it to stay taut becomes loose along the jawline and neck.
5
Temple hollowing
The temples thin noticeably, making the skull more visible and the face appear narrower and older.
6
Gaunt or aged overall appearance
The cumulative loss of facial fat volume ages the face — despite the body being at its healthiest weight.
Who is most at risk
Not everyone on a GLP-1 medication experiences dramatic facial changes. The key variables are speed of weight loss, total weight lost, age, and individual fat distribution. Patients who lose more than 15% of body weight, particularly those over 40, are most at risk for visible facial changes. Younger patients with stronger skin elasticity tend to show less dramatic facial aging from the same degree of weight loss.
Patients using the microdosing protocol — sub-therapeutic doses of Tirzepatide for metabolic optimization rather than aggressive fat loss — typically experience minimal facial changes because the rate and degree of weight loss are much lower.
How to treat it — the options at Plump
First Choice — Gradual Volume Restoration
Sculptra Biostimulator
Sculptra (poly-L-lactic acid) is the preferred treatment for GLP-1-related facial volume loss because it works gradually — stimulating the body's own collagen production over 3–6 months rather than immediately replacing volume with filler. This gradual approach is better suited to patients who may still be losing weight, as results develop alongside the body's changes rather than being added and then appearing disproportionate if additional weight is lost. Sculptra is injected across the cheeks, temples, and jawline. Results last 2+ years.
Structural Volume — Targeted Replacement
Dermal Fillers — Cheeks, Temples, Under-Eyes
Hyaluronic acid fillers provide immediate structural support in areas where volume loss is most visible. Under-eye hollowing, cheek deflation, and temple thinning all respond well to targeted filler placement. Best used after GLP-1 weight loss has stabilized — so that filler is not added to a face that is still changing week to week. RHA fillers are particularly well-suited to dynamic areas of the face during GLP-1 recovery.
Skin Laxity — Tightening & Remodeling
PiXel8 RF Microneedling
Rapid weight loss reduces collagen integrity in the skin, contributing to laxity especially along the lower face and jawline. RF microneedling stimulates new collagen production in the dermis to tighten and firm skin that has lost its structural support. This is most effective when started during weight loss rather than after significant laxity has already developed — earlier intervention preserves better baseline skin quality.
The most important thing most patients don't know
The optimal approach to GLP-1-related facial changes is to plan for them before they become severe — not to treat them reactively after maximum weight loss. This is one of the significant advantages of having your GLP-1 program and your aesthetic care managed by the same physician.
01
At GLP-1 program start
Baseline facial volume assessment. Discuss expected trajectory based on target weight loss. If skin quality concerns exist, start RF microneedling early — during weight loss, not after.
02
Mid-program (significant loss achieved)
Assess facial changes. If Sculptra is indicated, begin at this stage — gradual collagen stimulation develops alongside continued weight loss without overcorrecting.
03
At goal weight — stabilization phase
With weight stable, precise filler placement addresses residual hollowing. Final RF microneedling sessions for skin tightening. Results now visible against a stable baseline.
Plump Medical Spa is one of the only practices in Newport Beach that prescribes GLP-1 Tirzepatide programs and offers every aesthetic treatment needed to address the facial consequences — all under the same physician. Patients on the Tirzepatide program at Plump receive integrated facial planning as part of their care, not as a separate conversation at a different practice.
Frequently asked questions
What is Ozempic face?
Ozempic face is the facial volume loss and skin laxity that can occur with rapid GLP-1-related weight loss. The face tends to lose fat disproportionately during rapid weight loss, resulting in hollow cheeks, sunken under-eyes, and a more aged appearance despite a lower body weight.
Does everyone on Tirzepatide or Ozempic get Ozempic face?
No. The degree of facial change depends on speed and amount of weight loss, age, and individual fat distribution. Patients losing more than 15% of body weight rapidly and those over 40 are at highest risk. The GLP-1 microdosing protocol at Plump ($750/90 days) produces minimal facial changes due to its lower dose and slower weight loss trajectory.
What is the best treatment for Ozempic face?
Sculptra biostimulator is the preferred first-line treatment because its gradual collagen-stimulating mechanism suits patients who may still be losing weight. Dermal fillers address specific hollow areas once weight has stabilized. RF microneedling addresses skin laxity and is most effective when started during weight loss rather than after.
Can you treat Ozempic face while still on medication?
Yes — and proactive treatment during the weight loss journey often produces better outcomes than waiting. Sculptra in particular is well-suited to active weight loss phases because results develop gradually. Precise filler placement is typically deferred until weight stabilizes to avoid overcorrecting a changing baseline.
Does Plump offer both GLP-1 programs and facial aesthetic treatments?
Yes. Plump Medical Spa in Newport Beach is one of the only practices in Orange County offering physician-directed Tirzepatide programs alongside the full range of aesthetic treatments needed to address facial volume changes. Dr. Mortazavi manages both aspects of care for patients on GLP-1 programs.